InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
-0.13%
)
US TECH 100
19,440.80
(
-0.15%
)
Dow Jones
42,313.00
(
0.33%
)
Brent Oil
71.72
(
0.02%
)
Bitcoin
63,984.06
(
-2.50%
)
Post# of 253252
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120509
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: spartex post# 58624

Monday, 06/23/2008 7:42:14 AM

Monday, June 23, 2008 7:42:14 AM

Post# of 253252
ACHN will not spend any more of its own money on its HIV NRTI drug, elvucitabine, according to the CEO’s comments on the recent Needham webcast. This is probably a good decision—the drug’s commercial prospects are poor for the reasons mentioned in #msg-26540327.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up